key: cord-0075732-zvdbnkno
authors: Tritschler, Tobias; Le Gal, Grégoire; Brosnahan, Shari; Carrier, Marc
title: Rebuttal From Dr Tritschler et al
date: 2022-03-15
journal: Chest
DOI: 10.1016/j.chest.2022.01.039
sha: a68d209a0bbef27c183e4b1a85dda8f25bd76bc9
doc_id: 75732
cord_uid: zvdbnkno

nan

We agree with the point made by Jimenez et al 1 that consideration of bleeding risk is essential when evaluating administration of therapeutic anticoagulation. However, although well-intended, "first do not harm" is not an appropriate argument. If taken literally, anticoagulation could never be administered because it is well-known that anticoagulation increases the risk of bleeding. Instead, physicians must balance benefits with potential risks. Their assertion that therapeutic dose heparin should not be implemented for any patient because some patients that do not meet the eligibility criteria of randomized controlled trials (RCT) may not benefit is hard to follow. In fact, current clinical practice guideline recommendations on the use of therapeutic dose anticoagulation in different patient populations are based on RCTs that all used stringent eligibility criteria (Table 1 ). 2 These eligibility criteria are similar for the use of therapeutic heparin in acutely ill patients who are hospitalized with COVID-19. RCTs provide the best experimental design to study interventions; it is common to select participants who may gain the greatest benefit from the intervention. RCTs aim to provide evidence for relative treatment effectiveness under optimal conditions. 3 Such relative effects can often be applied to other populations, but physicians are required to estimate absolute risk differences that are based on relative benefits (or harms) and absolute baseline risks of an individual patient. 3 Some of the alleged limitations of RCTs evaluating therapeutic dose heparin in acutely ill patients with COVID-19 need to be addressed. 1 First, the fact that 20% of participants who were allocated to the therapeutic heparin arm in the multiplatform trial received less than therapeutic dose anticoagulation is not a reasonable concern. If anything, nonadherence to the study protocol would have diluted treatment effects and biased effect measures towards the null. The same is true for inclusion of participants up to 14 days after admission in the REMAP-CAP trial. Of note, only 13% of the acutely ill patient population of the multiplatform trial was enrolled in REMAP-CAP. Second, although potential interaction by co-treatment is a potential concern, Jimenez et al 1 use this one-sided argument: What if therapeutic heparin diminishes the efficacy of other established treatments that were studied in patients who did not receive therapeutic heparin? The urgency to find effective treatments for a novel disease left investigators no choice but to study interventions simultaneously. Third, the assumptions that patients were kept on organ support because of the open-label trial design are unfounded, speculative, and unlikely, given the shortage of ICU beds during the pandemic. Furthermore, Jimenez et al 1 criticize that none of the trials included VTE in the primary outcome, except for the HEP-COVID trial. Ascertainment bias of thrombotic events was the exact reason that trials did not include VTE in the primary outcome or, when they 

In patients with VTE, we recommend apixaban, dabigatran, edoxaban, or rivaroxaban over vitamin K agonist as treatment-phase anticoagulant therapy.

In patients with acute VTE in the setting of cancer, we recommend an oral Xa inhibitor over low-molecularweight heparin for the initiation and treatment phases of therapy. 

did, performed screening ultrasonography as in the HEP-COVID trial. Finally, requiring supplemental oxygen was not part of the definition of organ support in the multiplatform trial. Furthermore, and as outlined in our editorial, 4 physicians can define the most relevant threshold of organ support-free days based on their individual preference because treatment effect measures of the multiplatform trial can be applied to any threshold of cumulative probabilities on the scale.

As for any treatment of COVID-19, uncertainties remain, given the rapid evolution of the pandemic, novel virus variants, and new preventive and therapeutic options. However, best current evidence from four RCTs support the use of therapeutic heparin in acutely ill patients who were hospitalized with COVID-19 who were not at high risk of bleeding.

Point: Should therapeutic heparin be administered to acutely-ill hospitalized patients with COVID-19?

Antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report

Randomized clinical trials do not mimic clinical practice, thank goodness

Point: Should therapeutic heparin be administered to acutely-ill hospitalized patients with COVID-19?

Thromboprophylaxis in patients with COVID-19: a brief update to the CHEST Guideline and Expert Panel Report

Role of sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.Q6